Fresh from slashing its predictions for COVID-19 vaccine sales this year, mRNA specialist BioNTech has used some of its extensive cash reserves to bolster its pipeline in
A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack.
CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k
Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned wit
Draft guidance from NICE has recommended that nine artificial intelligence technologies can be used by NHS England to help plan the treatment of those undergoing external
Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.
AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio